Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia

Meta-analysis

Hiroyuki Uchida, Takefumi Suzuki, Hiroyoshi Takeuchi, Tamara Arenovich, David C. Mamo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.

Original languageEnglish
Pages (from-to)788-799
Number of pages12
JournalSchizophrenia Bulletin
Volume37
Issue number4
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Secondary Prevention
Antipsychotic Agents
Meta-Analysis
Schizophrenia
Treatment Failure
Hospitalization
Therapeutics
Recurrence
Information Storage and Retrieval
MEDLINE
Randomized Controlled Trials
Maintenance
Clinical Trials

Keywords

  • antipsychotic
  • dose
  • neuroleptic
  • relapse prevention
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia : Meta-analysis. / Uchida, Hiroyuki; Suzuki, Takefumi; Takeuchi, Hiroyoshi; Arenovich, Tamara; Mamo, David C.

In: Schizophrenia Bulletin, Vol. 37, No. 4, 07.2011, p. 788-799.

Research output: Contribution to journalArticle

@article{39200c6b6a5347e68a624eb8256af845,
title = "Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-analysis",
abstract = "Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50{\%} to <1 DDD) or very low dose (<50{\%} DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50{\%} to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.",
keywords = "antipsychotic, dose, neuroleptic, relapse prevention, schizophrenia",
author = "Hiroyuki Uchida and Takefumi Suzuki and Hiroyoshi Takeuchi and Tamara Arenovich and Mamo, {David C.}",
year = "2011",
month = "7",
doi = "10.1093/schbul/sbp149",
language = "English",
volume = "37",
pages = "788--799",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia

T2 - Meta-analysis

AU - Uchida, Hiroyuki

AU - Suzuki, Takefumi

AU - Takeuchi, Hiroyoshi

AU - Arenovich, Tamara

AU - Mamo, David C.

PY - 2011/7

Y1 - 2011/7

N2 - Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.

AB - Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.

KW - antipsychotic

KW - dose

KW - neuroleptic

KW - relapse prevention

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79959747688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959747688&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbp149

DO - 10.1093/schbul/sbp149

M3 - Article

VL - 37

SP - 788

EP - 799

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -